nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—narcolepsy	0.964	1	CbGaD
Thalidomide—Pomalidomide—TNF—narcolepsy	0.0066	1	CrCbGaD
Thalidomide—NFKB1—forebrain—narcolepsy	0.00205	0.143	CbGeAlD
Thalidomide—CRBN—forebrain—narcolepsy	0.00172	0.12	CbGeAlD
Thalidomide—FGFR2—brainstem—narcolepsy	0.00159	0.112	CbGeAlD
Thalidomide—FGFR2—forebrain—narcolepsy	0.00154	0.108	CbGeAlD
Thalidomide—CRBN—medulla oblongata—narcolepsy	0.00124	0.0869	CbGeAlD
Thalidomide—CRBN—midbrain—narcolepsy	0.00113	0.0794	CbGeAlD
Thalidomide—NFKB1—Leptin signaling pathway—SOCS2—narcolepsy	0.000959	0.0632	CbGpPWpGaD
Thalidomide—NFKB1—brain—narcolepsy	0.00085	0.0595	CbGeAlD
Thalidomide—CRBN—brain—narcolepsy	0.000713	0.0499	CbGeAlD
Thalidomide—FGFR2—brain—narcolepsy	0.000639	0.0447	CbGeAlD
Thalidomide—TNF—Monoamine Transport—HRH3—narcolepsy	0.000619	0.0408	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNFRSF1B—narcolepsy	0.000565	0.0372	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—SOCS2—narcolepsy	0.000559	0.0368	CbGpPWpGaD
Thalidomide—PTGS1—forebrain—narcolepsy	0.000489	0.0343	CbGeAlD
Thalidomide—PTGS2—forebrain—narcolepsy	0.000468	0.0327	CbGeAlD
Thalidomide—TNF—TNF receptor signaling pathway —TNFRSF1B—narcolepsy	0.00043	0.0284	CbGpPWpGaD
Thalidomide—NFKB1—Downstream TCR signaling—HLA-DQA1—narcolepsy	0.000425	0.028	CbGpPWpGaD
Thalidomide—NFKB1—Downstream TCR signaling—HLA-DQB1—narcolepsy	0.000397	0.0262	CbGpPWpGaD
Thalidomide—CYP2E1—medulla oblongata—narcolepsy	0.000367	0.0257	CbGeAlD
Thalidomide—NFKB1—Apoptosis—TNFRSF1B—narcolepsy	0.000349	0.023	CbGpPWpGaD
Thalidomide—PTGS2—medulla oblongata—narcolepsy	0.000338	0.0237	CbGeAlD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—SOCS2—narcolepsy	0.000334	0.022	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TNFRSF1B—narcolepsy	0.000327	0.0216	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNFRSF1B—narcolepsy	0.000324	0.0214	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—HLA-DRB1—narcolepsy	0.000321	0.0212	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—HLA-DQA1—narcolepsy	0.000317	0.0209	CbGpPWpGaD
Thalidomide—PTGS2—midbrain—narcolepsy	0.000309	0.0216	CbGeAlD
Thalidomide—NFKB1—Downstream TCR signaling—HLA-DRB1—narcolepsy	0.000302	0.0199	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—HLA-DQB1—narcolepsy	0.000297	0.0196	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TNFRSF1B—narcolepsy	0.000266	0.0175	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—TNFRSF1B—narcolepsy	0.000247	0.0163	CbGpPWpGaD
Thalidomide—CYP1A1—brain—narcolepsy	0.000231	0.0162	CbGeAlD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—narcolepsy	0.000227	0.0149	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—narcolepsy	0.000227	0.0149	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—HLA-DRB1—narcolepsy	0.000226	0.0149	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—HLA-DRB1—narcolepsy	0.000223	0.0147	CbGpPWpGaD
Thalidomide—CYP2E1—brain—narcolepsy	0.000211	0.0148	CbGeAlD
Thalidomide—PTGS1—brain—narcolepsy	0.000203	0.0142	CbGeAlD
Thalidomide—PTGS2—brain—narcolepsy	0.000194	0.0136	CbGeAlD
Thalidomide—TNF—Allograft Rejection—HLA-DQA1—narcolepsy	0.000191	0.0126	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.000189	0.0125	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DQB1—narcolepsy	0.000179	0.0118	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—narcolepsy	0.000174	0.0115	CbGpPWpGaD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—narcolepsy	0.00017	0.0112	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—narcolepsy	0.000157	0.0103	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—narcolepsy	0.000155	0.0102	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.000144	0.00951	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—narcolepsy	0.00014	0.00923	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DRB1—narcolepsy	0.000136	0.00897	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—narcolepsy	0.00013	0.00858	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—narcolepsy	0.00013	0.00858	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—narcolepsy	0.000126	0.00829	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—narcolepsy	0.000124	0.0082	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—narcolepsy	0.000122	0.00803	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CPT1B—narcolepsy	0.000121	0.00795	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—narcolepsy	0.00012	0.0079	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—narcolepsy	0.000116	0.00766	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—narcolepsy	0.000115	0.00755	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR2A—narcolepsy	0.000114	0.00751	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—narcolepsy	0.000113	0.00744	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SOCS2—narcolepsy	0.000109	0.0072	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—narcolepsy	0.000107	0.00706	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SOCS2—narcolepsy	0.000104	0.00683	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	0.0001	0.00661	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—narcolepsy	9.75e-05	0.00643	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—narcolepsy	9.3e-05	0.00613	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DQA1—narcolepsy	9.13e-05	0.00602	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—narcolepsy	8.68e-05	0.00572	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—narcolepsy	8.62e-05	0.00568	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DQB1—narcolepsy	8.54e-05	0.00563	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—narcolepsy	8.04e-05	0.0053	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—narcolepsy	8.04e-05	0.0053	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	7.96e-05	0.00525	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—narcolepsy	7.75e-05	0.00511	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—narcolepsy	7.63e-05	0.00503	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—narcolepsy	7.48e-05	0.00493	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	7.07e-05	0.00466	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—narcolepsy	6.88e-05	0.00454	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	6.82e-05	0.00449	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DRB1—narcolepsy	6.49e-05	0.00428	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—narcolepsy	6.13e-05	0.00404	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	5.78e-05	0.00381	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—narcolepsy	5.74e-05	0.00378	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HCRTR2—narcolepsy	5.54e-05	0.00365	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HCRTR1—narcolepsy	5.54e-05	0.00365	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—narcolepsy	5.44e-05	0.00359	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—narcolepsy	5.44e-05	0.00359	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	5.41e-05	0.00357	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—narcolepsy	5.37e-05	0.00354	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—P2RY11—narcolepsy	5.35e-05	0.00353	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	5.27e-05	0.00348	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HCRTR2—narcolepsy	5.26e-05	0.00347	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HCRTR1—narcolepsy	5.26e-05	0.00347	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—P2RY11—narcolepsy	5.08e-05	0.00335	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DQA1—narcolepsy	4.92e-05	0.00324	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—narcolepsy	4.9e-05	0.00323	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	4.8e-05	0.00317	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DQA1—narcolepsy	4.66e-05	0.00307	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—narcolepsy	4.62e-05	0.00304	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—narcolepsy	4.6e-05	0.00303	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DQB1—narcolepsy	4.6e-05	0.00303	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HCRT—narcolepsy	4.55e-05	0.003	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	4.51e-05	0.00297	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CHKB—narcolepsy	4.47e-05	0.00294	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DQB1—narcolepsy	4.36e-05	0.00288	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HCRT—narcolepsy	4.32e-05	0.00285	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—narcolepsy	4.17e-05	0.00275	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PENK—narcolepsy	4.06e-05	0.00267	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	3.93e-05	0.00259	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PENK—narcolepsy	3.85e-05	0.00254	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—narcolepsy	3.65e-05	0.00241	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	3.58e-05	0.00236	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CHKB—narcolepsy	3.55e-05	0.00234	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—narcolepsy	3.5e-05	0.0023	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—narcolepsy	3.47e-05	0.00229	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—narcolepsy	3.47e-05	0.00229	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TRH—narcolepsy	3.45e-05	0.00227	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CHKB—narcolepsy	3.34e-05	0.0022	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CHKB—narcolepsy	3.33e-05	0.0022	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—narcolepsy	3.32e-05	0.00219	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TRH—narcolepsy	3.27e-05	0.00216	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CHKB—narcolepsy	3.15e-05	0.00207	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	3.06e-05	0.00202	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CPT1B—narcolepsy	3.04e-05	0.002	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRH3—narcolepsy	3.02e-05	0.00199	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQA1—narcolepsy	2.98e-05	0.00197	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—narcolepsy	2.89e-05	0.0019	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRH3—narcolepsy	2.87e-05	0.00189	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQA1—narcolepsy	2.83e-05	0.00186	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQB1—narcolepsy	2.79e-05	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—narcolepsy	2.65e-05	0.00174	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CHKB—narcolepsy	2.58e-05	0.0017	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NPS—narcolepsy	2.51e-05	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TAC1—narcolepsy	2.51e-05	0.00165	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CPT1B—narcolepsy	2.41e-05	0.00159	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NPS—narcolepsy	2.38e-05	0.00157	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TAC1—narcolepsy	2.38e-05	0.00157	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHKB—narcolepsy	2.35e-05	0.00155	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CPT1B—narcolepsy	2.27e-05	0.0015	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CPT1B—narcolepsy	2.26e-05	0.00149	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CPT1B—narcolepsy	2.14e-05	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—narcolepsy	2.12e-05	0.0014	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—narcolepsy	2.01e-05	0.00133	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHKB—narcolepsy	2.01e-05	0.00132	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—narcolepsy	1.96e-05	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—narcolepsy	1.95e-05	0.00128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CPT1B—narcolepsy	1.75e-05	0.00115	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CPT1B—narcolepsy	1.6e-05	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—narcolepsy	1.51e-05	0.000993	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—narcolepsy	1.43e-05	0.000943	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CPT1B—narcolepsy	1.36e-05	0.000899	CbGpPWpGaD
